RxSight Q1 net loss widens 93.9% to $15.88 million; sales fall 18.5% to $30.89 million

• RxSight posted net loss of $15.88 million as sales fell 18.5% to $30.89 million.
• Operating loss widened to $17.83 million from higher SG&A, which climbed 11.2% to $31.86 million.
• Gross margin rose 1.3 percentage points to 76.1% on a favorable mix from a greater share of LAL sales.
• Quarterly LDD revenue dropped to $2.35 million on 20 units sold, while LAL revenue held at $27.04 million on 27,472 lenses sold.
• Cash, cash equivalents and short-term investments totaled $217.9 million, with management expecting that balance to fund operations for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RxSight Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-208921), on May 06, 2026, and is solely responsible for the information contained therein.